GlassScriptPhysician profile
Charles P Lee
NPI 1720089949
$554.78
in general payments reported to CMS, 2019-2025
11 companies · $170 in 2025
The $170 reported for 2025 was less than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $189 · 2021: $17.25 · 2022: $20.65 · 2023: $73.69 · 2024: $84.41 · 2025: $170.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $328.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $327.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sirtex Medical INC | $188.93 | 2019 | |
| Incyte Corporation | $143.10 | 2021-2025 | Zynyz |
| Bayer Healthcare Pharmaceuticals INC. | $49.74 | 2023-2024 | |
| Hologic Sales and Service, LLC | $32.13 | 2023 | Biozorb |
| Janssen Biotech, INC. | $25.64 | 2025 | Erleada, Akeega |
| Merck Sharp & Dohme LLC | $23.27 | 2024 | Lynparza, Keytruda |
| Alexion Pharmaceuticals, INC. | $20.65 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $18.89 | 2024 | Libtayo |
| Angiodynamics, INC. | $18.36 | 2025 | Smart Port Ct |
| Puma Biotechnology, INC. | $17.51 | 2023 | |
| Glaxosmithkline, LLC. | $16.56 | 2024 | Nucala |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.